Empagliflozin Tablets

Form: Tablets

Strength: 10 mg, 25 mg

Reference Brands: Jardiance(EU & US)

Category: Diabetes

Empagliflozin is a selective SGLT2 inhibitor approved for managing type 2 diabetes mellitus, heart failure, and chronic kidney disease. In the USA, the FDA approved Jardiance (10 mg, 25 mg) in 2014. In the EU, it is authorized by the EMA under centralized procedure. It is often prescribed as monotherapy or in combination with metformin or insulin. Empagliflozin improves glycemic control and reduces cardiovascular risks. Regular renal monitoring is advised. Pharmatradz.com connects global buyers and suppliers with licensed manufacturers of Empagliflozin, ensuring regulatory-compliant sourcing for B2B needs in both regulated and semi-regulated markets.